Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Toledano-Fonseca M, Gómez-España MA, Élez E, Grávalos C, García-Alfonso P, Rodríguez R, Losa F, Alés Díaz I, Graña B, Valladares-Ayerbes M, García-Ortiz MV, Polo E, Salgado M, Rivera F, Safont MJ, Salud A, Ruiz-Casado A, Tabernero JM, Riesco MC, Rodríguez-Ariza A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Toledano-Fonseca M, et al. Among authors: salud a. Biomed Pharmacother. 2023 Mar;159:114272. doi: 10.1016/j.biopha.2023.114272. Epub 2023 Jan 25. Biomed Pharmacother. 2023. PMID: 36706629 Free article.
Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer.
Morales S, Velasco A, Gasol A, Córdoba F, Vidal J, Serrate A, Valls J, Samame JC, Gisbert R, Moral D, Llombart-Cussac A, Salud A, Matias-Guiu X. Morales S, et al. Among authors: salud a. Cancer Treat Res Commun. 2018;16:13-17. doi: 10.1016/j.ctarc.2018.04.003. Epub 2018 Apr 25. Cancer Treat Res Commun. 2018. PMID: 31298997
Clinical guideline SEOM: hepatocellular carcinoma.
Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Sastre J, et al. Among authors: salud a. Clin Transl Oncol. 2015 Dec;17(12):988-95. doi: 10.1007/s12094-015-1451-3. Epub 2015 Nov 25. Clin Transl Oncol. 2015. PMID: 26607931 Free PMC article.
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. Carrato A, et al. Among authors: salud a. BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7. BMC Cancer. 2019. PMID: 31159765 Free PMC article. Clinical Trial.
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Martínez-Marín V, Maurel J. Feliu J, et al. Among authors: salud a. Br J Cancer. 2014 Jul 15;111(2):241-8. doi: 10.1038/bjc.2014.346. Epub 2014 Jun 19. Br J Cancer. 2014. PMID: 24946000 Free PMC article. Clinical Trial.
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, García-Albéniz X, Maurel J. Alonso V, et al. Among authors: salud a. Neoplasia. 2018 Jul;20(7):678-686. doi: 10.1016/j.neo.2018.05.004. Epub 2018 May 26. Neoplasia. 2018. PMID: 29842993 Free PMC article.
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis.
García-Alfonso P, Díaz-Rubio E, Abad A, Carrato A, Massutí B, Ortiz-Morales MJ, Manzano Mozo JL, Muñoz A, Durán G, Sastre J, Safont MJ, Ferreiro R, Rivera F, González E, Valladares-Ayerbes M, Grávalos C, Alonso-Orduña V, Viéitez JM, Yubero A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). García-Alfonso P, et al. Drugs Aging. 2021 Mar;38(3):219-231. doi: 10.1007/s40266-021-00834-w. Epub 2021 Feb 22. Drugs Aging. 2021. PMID: 33615402 Free PMC article.
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
Patel UB, Brown G, Machado I, Santos-Cores J, Pericay C, Ballesteros E, Salud A, Isabel-Gil M, Montagut C, Maurel J, Ramón-Ayuso J, Martin N, Estevan R, Fernandez-Martos C. Patel UB, et al. Among authors: salud a. Ann Oncol. 2017 Feb 1;28(2):344-353. doi: 10.1093/annonc/mdw616. Ann Oncol. 2017. PMID: 28426108 Free article. Clinical Trial.
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Santos C, Azuara D, Viéitez JM, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar R. Santos C, et al. Among authors: salud a. Ann Oncol. 2019 May 1;30(5):796-803. doi: 10.1093/annonc/mdz082. Ann Oncol. 2019. PMID: 30840064 Free article. Clinical Trial.
101 results